Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01699152 | Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 | 16 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00374933 | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 |
| NCT00850057 | Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 1 | 16 | University of California, San DiegoOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT04012879 | Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia | unknown | Phase 1 | 12 | Chinese PLA General HospitalOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT00634881 | Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 13 | German CLL Study GroupOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT00880815 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | completed | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | completed | Phase 1 | 58 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT02965092 | CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 80 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03366350 | Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 50 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT01216332 | Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients | completed | Phase 1 | 50 | Vanderbilt UniversityOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03588598 | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | unknown | Phase 1 | 40 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02310243 | Study of Palbociclib in MLL-rearranged Acute Leukemias | unknown | Phase 1 / Phase 2 | 50 | University of UlmOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia | suspended | Phase 1 | 20 | National University Health System, SingaporeOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Scripps HealthOTHER | 0 | Apr 11, 2019 | clinicaltrials |
| NCT00586924 | A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia | completed | Phase 1 | 49 | MedImmune LLCINDUSTRY | 2 | Apr 2, 2019 | clinicaltrials |
| NCT03881774 | Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 21, 2019 | clinicaltrials |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | terminated | Phase 1 / Phase 2 | 26 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00968253 | RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03854994 | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Yan'an Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00928200 | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | terminated | Phase 1 | 1 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 / Phase 2 | 9 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | withdrawn | Phase 1 | 0 | Michael ChoiOTHER | 0 | Jan 25, 2019 | clinicaltrials |
| NCT02086773 | Red Cell Transfusion Goals in Patients With Acute Leukemias | completed | Phase 1 | 90 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT00727415 | Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy(LLC0606) | completed | Phase 1 / Phase 2 | 42 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT00076180 | Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02240719 | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | completed | Phase 1 | 20 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | terminated | Phase 1 | 59 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 20, 2018 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT03757000 | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies | unknown | Phase 1 | 42 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03366324 | Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | unknown | Phase 1 / Phase 2 | 20 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT03671460 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 | 18 | Tianjin Mycure Medical Technology Co., LtdINDUSTRY | 1 | Sep 14, 2018 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01319864 | POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients | completed | Phase 1 | 20 | Seattle Children's HospitalOTHER | 2 | Sep 7, 2018 | clinicaltrials |
| NCT03613428 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | unknown | Phase 1 / Phase 2 | 12 | Sichuan UniversityOTHER | 0 | Aug 3, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01445132 | Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01910428 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL | terminated | Phase 1 | 14 | ERYtech PharmaINDUSTRY | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02226861 | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | completed | Phase 1 | 24 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03574168 | CD19-CAR-T Cells in Patients With R/R B-ALL | unknown | Phase 1 | 40 | Bioceltech Therapeutics, Ltd.INDUSTRY | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00504972 | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies | completed | Phase 1 | 23 | Weill Medical College of Cornell UniversityOTHER | 1 | May 29, 2018 | clinicaltrials |
| NCT01195480 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)(CD19TPALL) | terminated | Phase 1 / Phase 2 | 29 | University College, LondonOTHER | 2 | May 17, 2018 | clinicaltrials |
| NCT01558167 | A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia(CLL2P) | completed | Phase 1 / Phase 2 | 22 | German CLL Study GroupOTHER | 1 | May 15, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jul 25, 2019source: clinicaltrials